Anti-Human CD2 – Purified in vivo PLATINUM™ Functional Grade

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration.

Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco’s Purified Functional PLATINUM™ antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile.

Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at -80°C. Avoid Repeated Freeze Thaw Cycles.

Next Day 2-8°C

Clone G11 recognizes an epitope of human CD2.

CD2 is a 45-59 kD type I transmembrane glycoprotein belonging to the Ig superfamily. CD2 is the receptor for LFA-3/CD58. CD2 serves as an adhesion receptor that binds to CD58; generating the activation of CD2-positive T cells and NK cells and in the regulation of their cytolytic activities. CD2 is a specific marker for T cells and NK cells. Hence, it can be used in immunohistochemistry to identify the occurrence of these cells in tissue sections. The vast majority of T cell lymphomas and leukemias express CD2 which makes it possible to distinguish these conditions from B-cell lymphomas.

CD2 is present on normal peripheral blood lymphocytes, thymocytes, mature circulating T-cells and a subset of NK cells.

CD58 (LFA-3), CD48, CD59, CD15

1. Stern, LJ. et al. (2005) Proc Natl Acad Sci U S A.102(10):3744-9 PubMed
2. Woetmann, Anders et al. (2010) Experimental Dermatology 19: 1096–1102. Article Link
3. Meuer, S.C. et al. (1984) Cell 36:897
4. Peterson, A. and Sneed, B. (1987) Nature 329:842
5. Bierer, B.E. et al. (1989) Annu. Rev Immunol. 7:579
6. Krensky, C.F. et al. (1982) Proc. Natl. Acad. Sci. USA 79:7489
7. Krensky, C.F. et al. (1983) J. Immunol. 131:611